CN Patent

CN102065855A — 决奈达隆在制备用于预防因心血管疾病住院或死亡的药物中的用途

Assigned to Sanofi Aventis France · Expires 2011-05-18 · 15y expired

What this patent protects

决奈达隆或其药学上可接受的盐在制备用于预防因心血管疾病住院或死亡的药物中的用途。

USPTO Abstract

决奈达隆或其药学上可接受的盐在制备用于预防因心血管疾病住院或死亡的药物中的用途。

Drugs covered by this patent

dronedarone-hydrochloride (DRONEDARONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN102065855A
Jurisdiction: CN
Classification: —
Expires: 2011-05-18
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Aventis France
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.